Opportunities and Risks of a Single-Trial Default for FDA Drug Approval

Reshma Ramachandran, Rachel E. Sachs, Patricia J. Zettler, Holly Fernandez Lynch

Open source

DOI
10.1001/jamahealthforum.2026.2756
Published
2026-09-04
Container
JAMA Health Forum
Publisher
American Medical Association (AMA)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1001/jamahealthforum.2026.2756,
  title = {Opportunities and Risks of a Single-Trial Default for FDA Drug Approval},
  author = {Reshma Ramachandran and Rachel E. Sachs and Patricia J. Zettler and Holly Fernandez Lynch},
  year = {2026},
  journal = {JAMA Health Forum},
  doi = {10.1001/jamahealthforum.2026.2756},
  url = {https://doi.org/10.1001/jamahealthforum.2026.2756}
}

RIS

TY  - JOUR
TI  - Opportunities and Risks of a Single-Trial Default for FDA Drug Approval
AU  - Reshma Ramachandran
AU  - Rachel E. Sachs
AU  - Patricia J. Zettler
AU  - Holly Fernandez Lynch
PY  - 2026
JO  - JAMA Health Forum
DO  - 10.1001/jamahealthforum.2026.2756
UR  - https://doi.org/10.1001/jamahealthforum.2026.2756
ER  - 

APA

Ramachandran, R., Sachs, R. E., Zettler, P. J., & Lynch, H. F. (2026). Opportunities and Risks of a Single-Trial Default for FDA Drug Approval. JAMA Health Forum. https://doi.org/10.1001/jamahealthforum.2026.2756

Source records